Literature DB >> 34494080

Overexpression of AGR2vH, an oncogenic AGR2 spliced transcript, potentiates tumorigenicity and proteomic alterations in cholangiocarcinoma cell.

Juthamas Yosudjai1, Chaturong Inpad1, Phattarin Pothipan1, Saowaluk Saisomboon2,3, Damrasamon Surangkul1, Suchada Phimsen1, Nuttanan Hongsrichan2,4, Sopit Wongkham2,3, Siwanon Jirawatnotai5, Sittiruk Roytrakul6, Worasak Kaewkong1,2.   

Abstract

The upregulation of anterior gradient 2 (AGR2) has been observed in cholangiocarcinoma (CCA) cells, nras-mutant zebrafish, and specimens derived from CCA patients. Our previous study reported AGR2 splicing into AGR2vH to facilitate CCA cell aggressiveness, while this work aims to investigate the molecular mechanisms underlying AGR2vH. First, AGR2vH upregulation was demonstrated in CCA tissues derived from patients. For in vitro studies, established AGR2vH-overexpressing KKU-213A cells were found to exhibit increased proliferation and clonogenicity. In vivo tumorigenicity assessed in a mouse model represented higher tumorigenic potential in AGR2vH-overexpressing cell xenograft mice. Next, LC-MS/MS was analyzed, indicating that AGR2vH may be associated with CCA cell proliferation via Wnt/β-catenin signaling pathway activation, which was verified by β-catenin expression and nuclear translocation. The current results provide evidence that AGR2vH upregulation promotes tumorigenicity in CCA cells linked with an alteration of CCA cell proteome.
© The Author(s) 2021. Published by Oxford University Press on behalf of Japan Society for Bioscience, Biotechnology, and Agrochemistry.

Entities:  

Keywords:  AGR2; alternative splicing; cholangiocarcinoma; proteomics; tumorigenesis

Mesh:

Year:  2021        PMID: 34494080     DOI: 10.1093/bbb/zbab156

Source DB:  PubMed          Journal:  Biosci Biotechnol Biochem        ISSN: 0916-8451            Impact factor:   2.043


  1 in total

Review 1.  Impact of Alternative Splicing Variants on Liver Cancer Biology.

Authors:  Jose J G Marin; Maria Reviejo; Meraris Soto; Elisa Lozano; Maitane Asensio; Sara Ortiz-Rivero; Carmen Berasain; Matias A Avila; Elisa Herraez
Journal:  Cancers (Basel)       Date:  2021-12-21       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.